Lifecore Biomedical (LFCR) Earnings Call Presentation

Company Overview and Strategy - Lifecore is a fully integrated CDMO specializing in sterile injectable pharmaceuticals[9], aiming for a revenue CAGR of 12%+ and Adjusted EBITDA margins of 25%+ in the mid-term[7, 89] - The company projects revenues of $74 million - $76 million and Adjusted EBITDA of $12 million - $14 million for the 7-month transition period (May 26 – Dec 31, 2025)[10] - Lifecore has expanded capacity and revenue potential of approximately $300 million annually[7, 89] Market and Growth Drivers - The global injectable CDMO market is a $10 billion market with a +10% CAGR[24] - The global CDMO market is a $120 billion market with a +8% CAGR[24] - The Hyaluronic Acid market is a $9.8 billion market with a +7% CAGR[24] Financial Performance and Outlook - Fiscal Year 2025 revenues reached $128.9 million, a +0.5% increase compared to FY24[82] - Fiscal Year 2025 Adjusted EBITDA was $19.5 million, a -$0.7 million decrease compared to FY24[82] - The company is targeting a mid-term Adjusted EBITDA margin of 25%+[75] Pipeline and New Business - The total pipeline represents $150 million - $200 million in incremental commercial revenue potential[41] - The company has a strong and diverse pipeline with 11 active late-stage projects and 19 early-mid stage projects[42] - The company is expanding its target markets beyond high-viscosity legacy, including mAbs, complex generics, biologics, and GLP-1[55]